. Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures. Sci Adv. 2023 Dec;9(48):eadk6191. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. DNL151